Ataxia-telangiectasia (A-T) is a human autosomal recessive disease caused by mutations in the gene encoding ataxia-telangiectasia mutated (ATM). A-T is characterized by progressive cerebellar degeneration, variable immunodeficiency, and a high incidence of leukemia and lymphoma.
INTRODUCTION
aberrant T cell development characterized by a decrease in absolute numbers of thymocytes. In the thymus of Atm -/-mice the frequency of CD4 + CD8 + double-positive and CD4 -CD8 -double negative thymocytes is increased, while the frequency of CD4 and CD8 single-positive mature thymocytes is decreased when compared with normal mice [9] [10] [11] , suggesting that Atm may be required for transition of immature CD4 + 8 + doublepositive thymocytes to the mature single positive stage. It has been suggested that this apparent block in T cell development may also result in a marked reduction in the number of mature CD4 and CD8 T cells in the periphery 10 . In A-T patients, it has been reported that while total T cell numbers in the blood are similar to that observed in normal individuals, the frequency of naïve T cells is reduced, while the frequency of memory marker positive T cells is increased [12] [13] [14] .
A-T patients exhibit both thymic hypoplasia, resulting in decreased T cell production and immunodeficiency, and hematological malignancy. These abnormalities may result from defects intrinsic to hematopoietic stem cells (HSCs), or may reflect developmental defects in the thymic microenvironment in which the progeny of these cells mature.
Defects in thymic function, such as those observed in DiGeorge syndrome, are known to result in immunodeficiency (reviewed in 15 ). It has also been suggested that fetal thymus transplantation may reverse immunodeficiency observed in A-T by overcoming thymic hypotrophy (reviewed in 16 ). In addition, while thymic development of T cells is impaired in A-T patients, the function of mature T cells has been reported to be normal 12, 17 , suggesting that either a development-specific defect exists in T cell progenitors, or that the thymic microenvironment is unable to mediate efficient T cell maturation. We
For personal use only. on November 12, 2017 . by guest www.bloodjournal.org From hypothesized that if there were intrinsic defects in the HSCs of Atm -/-mice, the replacement of the hematopoietic compartment in these mice by bone marrow transplantation would overcome the observed hematologic abnormalities. Our results indicate that full donor-type hematopoiesis can be achieved in Atm -/-mice using clinically relevant host conditioning, resulting in restoration of normal immune system function. In addition, replacement of the Atm-deficient hematopoietic compartment prevents the occurrence of hematological malignancies in Atm-deficient mice. Therefore, bone marrow transplantation may prove to be of significant therapeutic benefit in A-T patients.
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METHODS

Animals
Atm
-/-knockout mice used as bone marrow donors for reconstitution of C3H recipients were the kind gift of Dr. Fred Alt (Children's Hospital, Boston, MA). Mice were obtained as heterozygotes and intercrossed to obtain homozygous progeny that were genotyped by PCR according to the protocol described by Dr. Skin grafts: Tail skin grafting was performed as previously described 21 .
Flow cytometry: Flow cytometry was performed after gating on live cells as previously described 22 . Cy-chrome conjugated anti-CD4 (RM4-5), PE conjugated anti-CD8 (53-
anti-CD44, PE conjugated anti-B220 (RA3-6B2), anti-CD122 (TM-B1), anti-CD3 and anti-CD11b were obtained from PharMingen (San Diego, CA).
Statistics: All statistical calculations were performed using GraphPad Prism 2.01 software (GraphPad Software Inc., San Diego CA). The Kaplan and Meier method with a 95% confidence interval was used for the calculation of survival curves. Comparison of survival curves was performed using the log rank test. Two tailed T tests were used for all other statistics.
RESULTS
Defects in lymphocyte development observed in Atm
-/-mice are stem cell intrinsic.
To determine if defects in T cell development observed in Atm -/-mice were due defects in the ability of the thymic environment to support T cell maturation, we monitored the development of Atm -/-mutant-derived T cells in wild-type mice with a normal thymus. allografts. These data suggest that bone marrow transplantation can be used to overcome defects in T cell development that lead to immunodeficiency in Atm deficient mice.
In Atm -/-mice, non-myeloablative conditioning consisting of T cell depletion and administration of cyclophosphamide was sufficient to induce full donor-type chimerism.
However, the same preparative regimen failed to induce donor-type chimerism in wildtype mice. These data suggest that barriers to bone marrow engraftment are significantly reduced in Atm -/-mice 24 . It is possible that reduced barriers to engraftment of donor-type bone marrow may reflect a competitive disadvantage of Atm -/-bone marrow as a result of cell intrinsic defects, and as a result these cells may be unable to compete with wild-type cells for bone marrow niches. Alternately, Atm deficiency may increase sensitivity to the immunosuppressive effects of cyclophosphamide which in turn may allow donor bone marrow to engraft more efficiently by reducing anti-donor immune responses more effectively than in wild-type mice. A-T patients appear to be more susceptible to sideeffects from agents such as cyclophosphamide 5 . Previous work has suggested that host T cell depletion is critical for efficient bone marrow engraftment 22, 25, 26 . In so far as Atm -/-mice exhibit reduced numbers of mature T cells, it is also possible that immunodeficiency observed in Atm -/-mice may reduce the requirement for rigorous myeloablation to achieve donor bone marrow engraftment. Regardless of the mechanism that allows for full replacement of the hematopoietic compartment in Atm -/-mice using relatively mild host conditioning, our results suggest that similar defects in humans may make it possible to achieve full donor-type chimerism with minimal conditioning.
Although it remains to be determined how the use of cytoreductive drugs will be tolerated in A-T patients, cyclophosphamide is routinely used in patients receiving bone marrow transplants [27] [28] [29] [30] [31] . In addition, several clinical protocols using human-specific T cell depletion and cyclophosphamide have been shown to be tolerated in humans 32 , and therefore we suggest that it may be possible to develop similar conditioning regimens that will be clinically relevant. The ability to achieve full donor chimerism using a relatively non-toxic host conditioning regimen would make bone marrow transplantation a clinically acceptable means to address hematological defects associated with A-T. inducing full donor-type chimerism, it is presently unclear whether full donor type chimerism is necessary in order to reduce the occurrence of lymphoma. We are currently investigating the level of donor-type chimerism needed achieve significant protection from lymphoma, and determining if solid tumors develop in these mice as they age.
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The demonstration that bone marrow transplantation may overcome immune system defects and the occurrence of hematological malignancy in Atm -/-mice opens up the possibility that similar therapies may eventually be able to alleviate these major causes of morbidity and mortality in A-T patients.
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